Citi opened an "upside 90-day catalyst watch" on shares of Agilent while keeping a Buy rating on the name with a $185 price target. The share overhang of a potential transformational acquisition should be removed with Agilent's deal for Biocare Medical, the analyst tells investors in a research note. Citi sees the stock's multiple rebounding.
